

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1477)

**POLL RESULTS OF THE EXTRAORDINARY
GENERAL MEETING HELD ON OCTOBER 16, 2024**

The Board announces that all the resolutions as set out in the Notice were duly passed by the Shareholders as ordinary resolutions by way of poll at the EGM.

The board of directors (the “**Board**”) of Ocumention Therapeutics (the “**Company**”) is pleased to announce the poll results of the extraordinary general meeting of the Company (the “**EGM**”) held at 56th Floor, One Museum Place Office Building, No. 669 Xinzha Road, Shanghai, PRC on Wednesday, October 16, 2024 at 10:00 a.m.

References are made to the Company’s circular (the “**Circular**”) in connection with the EGM and notice of the EGM (the “**Notice**”) both dated September 30, 2024. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The voting results in respect of the resolutions proposed at the EGM were as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	The terms of the Transaction Documents dated August 12, 2024 and the Transaction contemplate thereunder and implementation of be and are hereby approved, ratified and confirmed.	487,101,091 (99.973496%)	129,137 (0.026504%)
2.	Subject to the fulfilment of the conditions precedent of the Share Issue, the Directors be and are hereby granted a specific mandate to allot and issue 139,159,664 Consideration Share to Alcon Pharma as consideration for the Acquisition and In-Licensing.	487,115,091 (99.976369%)	115,137 (0.023631%)
3.	The proposed annual caps (where applicable) in relation to the Transactions contemplated under the Transaction Documents, be and are hereby approved.	487,101,091 (99.973496%)	129,137 (0.026504%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
4.	Any one or more Director(s) be and is/are hereby authorized for and on behalf of the Company to sign, execute and deliver all such Transaction Documents (including under seal, where applicable), to do all other acts and things deemed by him/her/them to be incidental to, ancillary to or in connection with the matters contemplated in the Transaction Documents and the completion of the Transaction, and take such action as may in the opinion of the Director(s) be necessary, desirable or expedient to implement and give effect to or in connection with the Transaction Documents and the Transactions contemplated thereunder and the proposed annual caps in relation thereto (where applicable), and to agree to such variation, amendments or waiver or matters relating to the Transaction Documents (including any variation, amendments or waiver of such Transaction Documents or any terms thereof) as is/are, in the opinion of such Director(s) or the duly authorized committee of the board of Directors, in the interest of the Company and its shareholders as a whole.	487,101,091 (99.973496%)	129,137 (0.026504%)

Please refer to the Notice for the full text of the resolutions proposed at the EGM.

The total number of issued Shares as of the EGM was 680,208,350 Shares (excluding treasury Shares), which was the total number of Shares entitling the Shareholders to attend and vote for or against all resolutions at the EGM. As of the EGM, there were (i) 13,446,500 treasury Shares held by the Company (including any treasury Shares held or deposited with CCASS) and as such no voting rights of treasury Shares have been exercised at the EGM; and (ii) no Shares repurchased by the Company which are pending cancellation and should be excluded from the total number of Shares for the purpose of the EGM. There were no Shares entitling the holders to attend and abstain from voting in favor at the EGM as set out in Rule 13.40 of the Listing Rules. There were no restrictions on any Shareholders casting votes on any of the proposed resolutions at the EGM. No Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the EGM and no Shareholder has stated his/her/its intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the EGM.

The executive Directors, Mr. Ye LIU and Dr. Zhaopeng HU, the non-executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG and the independent non-executive Directors, Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG attended the EGM, either in person or by means of telecommunication.

Computershare Hong Kong Investor Services Limited, the Hong Kong branch share registrar and transfer office of the Company, acted as the scrutineer for counting of votes at the EGM.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, October 16, 2024

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.